| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Regenerative Medical Technology Group Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.042 |
| 52 Week High | US$0.06 |
| 52 Week Low | US$0.0072 |
| Beta | 1.49 |
| 11 Month Change | 7.16% |
| 3 Month Change | -14.16% |
| 1 Year Change | 237.22% |
| 33 Year Change | -72.59% |
| 5 Year Change | -39.30% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| MSSV | US Specialty Retail | US Market | |
|---|---|---|---|
| 7D | 21.4% | -1.4% | 1.8% |
| 1Y | 237.2% | 15.2% | 24.0% |
Return vs Industry: MSSV exceeded the US Specialty Retail industry which returned 15% over the past year.
Return vs Market: MSSV exceeded the US Market which returned 23.6% over the past year.
Price Volatility
| MSSV volatility | |
|---|---|
| MSSV Average Weekly Movement | n/a |
| Specialty Retail Industry Average Movement | 6.8% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: MSSV's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine MSSV's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 1 | Dave Christensen | regenmedtechgroup.com |
Regenerative Medical Technology Group Inc. engages in the stem cell therapy business in the United States and internationally. It provides CELLGENIC FLOW EXOSOMES for hair loss and pain management; CELLGENIC Mesenchymal Stem Cell, which excretes growth factors, cytokines, and proteins for regeneration of tissue; CELLGENIC LYOPHILIZED EXOSOMES that is derived from human umbilical cord mesenchymal stem cells, including potent growth factors, peptides, coenzymes, minerals, amino acids, vitamins and UV radiation reducing agents for skin revitalization; and VITANOVAS that offers in-home treatments to patients in need of immune modulation to help fight infections, viruses, and diseases. The company also offers GCELL, a closed-system medical device to harness the natural and restorative capabilities of adipose tissue; CELLGENIC SVF, an isolation kit system that has the ingredients and consumables for the extraction of adipose-derived stem cells from fat; CELLGENIC BONE MARROW; CELLGENIC Platelet Rich Plasma for healing and reducing inflammation; CELLGENIC HUMAN PLACENTA; and CELLGENIC ALLOGENEIC PRP.
Regenerative Medical Technology Group Inc. Fundamentals Summary
| MSSV fundamental statistics | |
|---|---|
| Market cap | US$552.48k |
| Earnings (TTM) | -US$10.10m |
| Revenue (TTM) | US$2.44m |
0.2x
P/S Ratio-0.1x
P/E RatioIs MSSV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MSSV income statement (TTM) | |
|---|---|
| Revenue | US$2.44m |
| Cost of Revenue | US$732.93k |
| Gross Profit | US$1.71m |
| Other Expenses | US$11.81m |
| Earnings | -US$10.10m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.81 |
| Gross Margin | 69.97% |
| Net Profit Margin | -413.98% |
| Debt/Equity Ratio | -78.6% |
How did MSSV perform over the long term?
See historical performance and comparison